Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs W W Grainger Inc (GWW) Price & Performance

Cassava Sciences IncTrade
W W Grainger IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs W W Grainger Inc — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while W W Grainger Inc trades at $1,311.58 (market cap $61.32B). The key difference: W W Grainger Inc is far larger — about 1284.2× Cassava Sciences Inc's market cap, and W W Grainger Inc pays a 0.77% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAGWW
Market Cap
$47.75M$61.32B
Sector
HealthTechnology
52-Week High
$4.64$1.40K
52-Week Low
$0.87$918.18
Enterprise Value
-$34.93M$63.53B
Dividend Yield
0.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.

The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.

W W Grainger Inc

W.W. Grainger (GWW) trades at $1,299.53, showing modest daily gains of 0.16%. The stock demonstrates strong fundamental performance with Q2 2026 earnings beating estimates at $12.01 per share versus $11.30 expected, and revenue reaching $5 billion. Technical indicators show bearish momentum with the current price between support at $1,282 and resistance at $1,305. The company raised its full-year 2026 outlook following strong quarterly results driven by margin expansion and market share gains.

GWW presents a mixed investment case with strong profitability metrics (ROE 47.92%, net margin 9.92%) offset by premium valuation (P/E 33.19). Analyst consensus leans cautious with 65.79% hold ratings despite recent earnings beats. Key risks include valuation concerns and competitive pressures in industrial distribution. The $1,320 consensus price target suggests limited upside from current levels, requiring careful monitoring of margin sustainability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About W W Grainger Inc

Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.

Read more on GWW